Brazil finds Sinovac’s vaccine efficacy well below earlier findings
São Paulo-based Butantan Institute lists an efficacy rate of 50.4%, after pressure for more transparency
12 January 2021 - 22:52
São Paulo — Brazil officials said on Tuesday the Coronavac vaccine developed in partnership with China's Sinovac Biotech was 50.38% effective in preventing coronavirus cases, a number that meets the threshold required by global regulators for approval but that’s well below the 78% figure announced last week.
At a press conference Tuesday, São Paulo state officials and researchers from Butantan Institute explained that they split the cases in six categories: asymptomatic, very mild, mild, two levels of moderate, and severe — the first two not requiring medical assistance...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.